GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Agile Therapeutics Inc (OTCPK:AGRX) » Definitions » Book Value per Share

Agile Therapeutics (Agile Therapeutics) Book Value per Share : $-5.51 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Agile Therapeutics Book Value per Share?

Agile Therapeutics's book value per share for the quarter that ended in Dec. 2023 was $-5.51.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Agile Therapeutics was -18.10% per year. The lowest was -62.00% per year. And the median was -23.60% per year.

Agile Therapeutics's current price is $0.445. Its book value per share for the quarter that ended in Dec. 2023 was $-5.51. Hence, today's PB Ratio of Agile Therapeutics is .

During the past 12 years, the highest P/B Ratio of Agile Therapeutics was 15.14. The lowest was 1.01. And the median was 4.19.


Agile Therapeutics Book Value per Share Historical Data

The historical data trend for Agile Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agile Therapeutics Book Value per Share Chart

Agile Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,310.75 1,126.73 64.50 -6.45 -5.51

Agile Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.45 -10.12 -7.39 -5.45 -5.51

Competitive Comparison of Agile Therapeutics's Book Value per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Agile Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agile Therapeutics's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Agile Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Agile Therapeutics's PB Ratio falls into.



Agile Therapeutics Book Value per Share Calculation

Agile Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-16.32-0.00)/2.96
=-5.51

Agile Therapeutics's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-16.32-0.00)/2.96
=-5.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Agile Therapeutics  (OTCPK:AGRX) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Agile Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Agile Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Agile Therapeutics (Agile Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
500 College Road East, Suite 310, Princeton, NJ, USA, 08540
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
Executives
Scott M Coiante officer: Chief Financial Officer 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Josephine Torrente director 101 POOR FARM ROAD, PRINCETON NY 08540
Sandra Carson director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
John W Hubbard director 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Sharon Surrey Barbari director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Amy Welsh officer: Chief Commercial Officer 500 COLLEGE ROAD EAST, SUITE 310, C/O AGILE THERAPEUTICS, INC., PRINCETON NJ 08540
Alfred Altomari director, officer: Chief Executive Officer C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Dennis Reilly officer: Chief Financial Officer 600 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jason Butch officer: Principal Accounting Officer 101 POOR FARM ROAD, PRINCETON NJ 08540
Paul Korner officer: Sr. VP & Chief Medical Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Abhijeet J Lele director, See remarks C/O EP MEDYSTEMS, 575 RTE 73 N, WEST BERLIN NJ 08091
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

Agile Therapeutics (Agile Therapeutics) Headlines